Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective.
Amantadine and rimantadine are recommended for the treatment and prophylaxis of influenza A infections, and constitute an integral component of influenza control measures in the nursing home setting. However, optimal use necessitates a thorough understanding of the toxicity profiles of these agents, as well as strategies to reduce the risk of adverse reactions. Adverse reactions of these compounds predominantly involve the gastrointestinal tract and the central nervous system (CNS), including hyperexcitability, slurred speech, tremors, insomnia, dizziness, mood disturbance, ataxia, psychosis and fatigue. Based on data from comparative trials, rimantadine appears to exhibit a lesser propensity to cause adverse CNS reactions than amantadine, but a similar propensity to cause adverse gastrointestinal reactions. Factors enhancing the risk of adverse reactions to these agents include reduced renal function (especially for amantadine), drug-drug interactions with cationic drugs, which inhibit amantadine renal tubular secretion (e.g. trimethoprim, triamterene, and possibly cimetidine and procainamide), elevated peak and trough plasma concentrations, and a history of seizures. Careful attention to published dosage adjustment guidelines for these compounds, avoidance of interacting drugs and avoiding these agents in patients with a history of seizures may be the best means to reduce the risk of toxicity in elderly patients. Rimantadine may have an advantage over amantadine in the elderly population in light of its lesser propensity to cause adverse reactions, less complex dosage adjustment in the case of renal impairment and probable lack of drug-drug interaction potential with cationic drugs.
Guay
D R
DR
College of Pharmacy, University of Minnesota, Minneapolis.
D000368:Aged; D000547:Amantadine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006707:Homes for the Aged; D006801:Humans; D009980:Influenza A virus; D007251:Influenza, Human / Q000517:prevention & control*; D009735:Nursing Homes; D012299:Rimantadine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use
D012299:Rimantadine; D000547:Amantadine